Vergleich

Anti-Bundibugyo Ebolavirus, GP (Clone BDBV-255) - Purified No Carrier Protein - 250 µg

ArtNr LEIN-E168-250ug
Hersteller Leinco Technologies
Menge 250 ug
Quantity options 1 mg 250 ug
Kategorie
Typ Antibody Monoclonal
Applikationen ELISA, EM, FA, other
Clon BDBV-255
Specific against other
ECLASS 10.1 42030590
ECLASS 11.0 42030590
UNSPSC 12352203
Versandbedingung Gekühlt
Lieferbar
Manufacturer - Applications
B, ELISA, EM, FA, N
Manufacturer - Category
Primary Monoclonal Antibodies>Infectious Diseases|Monoclonal Antibodies|Recombinant Antibodies
Manufacturer - Targets
Bundibugyo Ebolavirus, Glycoprotein
Shipping Temperature
Standard Overnight on Blue Ice.
Storage Conditions
This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Product Description
Ebola virus is a member of the Filoviridae family that causes severe disease in humans with a mortality rate of 25-90%1. Three Ebola species are responsible for lethal outbreaks: Zaire ebolavirus (EBOV), Bundibugyo ebolavirus (BDBV), and Sudan ebolavirus (SUDV). The Ebola virus envelope contains a single surface glycoprotein (GP) which is responsible for viral attachment to the host cell, endosomal entry, and membrane fusion1. GP is composed of two subunits, GP1 and GP2. GP1 has a heavily glycosylated mucin-like domain and a glycan cap. GP2 contains the internal fusion loop, transmembrane domain, and stalk. GP is the major target of neutralizing monoclonal antibody (mAb) and vaccine design against Ebola virus. mAbs targeting GP1 are capable of neutralizing all known filovirus GPs2, 3. A pan-Ebola virus mAb is highly desirable to protect against future outbreaks. BDBV-255 is a GP mAb isolated from B cells of a survivor of the 2007 Uganda BDBV outbreak3. Peripheral blood mononuclear cells from the survivor were transformed with Epstein-Barr virus, CpG, and additional supplements. Subsequently, cell supernatants were screened by ELISA for binding to GPs from BDBV, EBOV, or MARV filoviruses. Positive cells were fused with HMMA2.5 myeloma cells by electrofusion and cloned by single-cell fluorescence-activated cell sorting. In binding and neutralization assays, BDBV-255 binds to and neutralizes BDBV but not other filoviruses3. BDBV-255 targets an epitope that extends below the base of GP, possibly within the membrane-proximal external region (MPER) of GP2, in a region that is likely not conserved between filoviruses. Stable binding may require the full MPER, transmembrane domain regions, and a membrane. One GP trimer is able to accommodate three BDBV-255 antibodies.
Manufacturer - Research Area
Category A Pathogens, Infectious Disease, Viral, IVD Raw Material
Concentration
≥1.0 mg/ml
Formulation
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Antigen Distribution
Ebola virus glycoprotein is a surface protein expressed on the virusenvelope.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 250 ug
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen